Does AbbVie Have 'Unclean Hands' From Building Humira Patent Thicket? Judge Allows Discovery
Magistrate judge says Boehringer's theory 'may or may not be viable' as an infringement defense; permits third party subpoenas for information on clinical trials.
You may also be interested in...
Unjustifiable Delays In Generic Competition? Biopharma Contends There Is No Problem
As Congress prepares to again debate patent reforms, brand industry says allegations of ‘patent thickets’ and extended market exclusivity are based on inaccurate or misleading data. They assert there is no need for PTO and FDA to institute systemic policy changes.
Unlikely Foe Gets AbbVie To Alter Humira Marketing Practices In California
Under $24m settlement with the California Department of Insurance, AbbVie’s nurse ‘ambassadors’ cannot participate in conversations between patients and insurance companies and must disclose that they are paid by the company.
AbbVie's 'Unjustified' Humira Settlements Divide Market, Claims Class Action
First suit challenging biosimilar litigation settlements ratchets up pressure on AbbVie's "patent thicket" and licensing strategy.